OBJECTIVE: This study tested whether a relationship exists between concentration and response following discontinuation of selective serotonin reuptake inhibitors. METHOD:Eight patients with remitted major depression who were taking 20 mg/day of eitherfluoxetine or paroxetine underwent placebo substitution for 3 days. Serum drug and brain fluorine levels were obtained before and after placebo substitution. RESULTS: With placebo substitution, a mean of 88% (SD=13%) of brain fluorine signal from fluoxetine (plus fluorinated metabolites) remained, compared with a mean of 38% (SD=17%) of the brain fluorine signal from paroxetine (plus fluorinated metabolites). Among patients taking paroxetine, adverse events during placebo substitution correlated highly with steady-state brain drug levels. CONCLUSIONS: The correlation of clinical effects with brain drug levels in the paroxetine group suggests that relationships between drug response and brain drug concentrations merit further investigation.
RCT Entities:
OBJECTIVE: This study tested whether a relationship exists between concentration and response following discontinuation of selective serotonin reuptake inhibitors. METHOD: Eight patients with remitted major depression who were taking 20 mg/day of either fluoxetine or paroxetine underwent placebo substitution for 3 days. Serum drug and brain fluorine levels were obtained before and after placebo substitution. RESULTS: With placebo substitution, a mean of 88% (SD=13%) of brain fluorine signal from fluoxetine (plus fluorinated metabolites) remained, compared with a mean of 38% (SD=17%) of the brain fluorine signal from paroxetine (plus fluorinated metabolites). Among patients taking paroxetine, adverse events during placebo substitution correlated highly with steady-state brain drug levels. CONCLUSIONS: The correlation of clinical effects with brain drug levels in the paroxetine group suggests that relationships between drug response and brain drug concentrations merit further investigation.
Authors: Kwan L Ng; Ellen M Gibson; Robert Hubbard; Juemin Yang; Brian Caffo; Richard J O'Brien; John W Krakauer; Steven R Zeiler Journal: Stroke Date: 2015-08-20 Impact factor: 7.914
Authors: Yan Feng; Bruce G Pollock; Robert E Ferrell; Mark A Kimak; Charles F Reynolds; Robert R Bies Journal: Br J Clin Pharmacol Date: 2006-05 Impact factor: 4.335
Authors: Francis E Lotrich; Bruce G Pollock; Margaret Kirshner; Robert F Ferrell; Charles F Reynolds Iii Journal: J Psychiatry Neurosci Date: 2008-03 Impact factor: 6.186
Authors: Michael E Henry; Nicolas R Bolo; Chun S Zuo; Rosemond A Villafuerte; Kenroy Cayetano; Paul Glue; Bharat D Damle; Emma Andrews; Tara L Lauriat; Namoode S Rana; Jeffrey H Churchill; Perry F Renshaw Journal: Antimicrob Agents Chemother Date: 2013-08-12 Impact factor: 5.191
Authors: Kelly A Meulendyke; Suzanne E Queen; Elizabeth L Engle; Erin N Shirk; Jiayang Liu; Joseph P Steiner; Avindra Nath; Patrick M Tarwater; David R Graham; Joseph L Mankowski; M Christine Zink Journal: J Neurovirol Date: 2014-09-17 Impact factor: 2.643